Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6572-6580

  Zhao, Wei ^a,b,c,d   Hill, Helen ^e,f   Guellec, Chantal Le ^g   Neal, Tim ^h   Mahoney, Sarah ⁱ   Paulus, Stephane ⁱ   Castellan, Charlotte ^j   Kassai, Behrouz ^j   Van Den Anker, Johannes N ^k,l,m,n   Kearns, Gregory L ^o,p   Turner, Mark A ^e,f   Jacqz Aigrain, Evelyne ^b,c,d  

^a SHANDONG UNIVERSITY   (China)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c INSERM   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f LIVERPOOL WOMEN S HOSPITAL   (United Kingdom)

^g UNIVERSITÉ DE TOURS   (France)

^h ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

ⁱ ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^j UNIVERSITÉ DE LYON   (France)

^k SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^l CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^m GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

ⁿ UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^o CHILDREN S MERCY HOSPITAL   (United States)

^p UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; CAFFEINE; CIPROFLOXACIN; COLISTIN; CREATININE; DIURETIC AGENT; INOTROPIC AGENT; NYSTATIN; TEICOPLANIN; TOBRAMYCIN; ANTIINFECTIVE AGENT; CARDIOTONIC AGENT;

AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; COMPUTER PROGRAM; CREATININE BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG OVERDOSE; DRUG PENETRATION; FEMALE; GESTATIONAL AGE; GROUPS BY AGE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NEWBORN; OPTIMAL DRUG DOSE; PERINATAL PERIOD; POPULATION; RISK FACTOR; SEPSIS; BLOOD; CEREBROSPINAL FLUID; DOSE RESPONSE; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NEWBORN INTENSIVE CARE; OFF LABEL DRUG USE; PROSPECTIVE STUDY;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BODY WEIGHT; CARDIOTONIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIPROFLOXACIN; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GESTATIONAL AGE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INTENSIVE CARE, NEONATAL; MALE; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; OFF-LABEL USE; PROSPECTIVE STUDIES;

EID: 84908272329     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03568-14     Document Type: Article

References (31)

1. Gendrel D, Chalumeau M, Moulin F, Raymond J. 2003. Fluoroquinolones in paediatrics: a risk for the patient or for the community? Lancet Infect. Dis. 3:537-546. http://dx.doi.org/10.1016/S1473-3099(03)00736-9.
2. Gray JW, Patel M. 2011. Management of antibiotic-resistant infection in the newborn. Arch. Dis. Child. Educ. Pract. Ed. 96:122-127. http://dx.doi.org/10.1136/adc.2010.199653.
3. Kaguelidou F, Turner MA, Choonara I, Jacqz-Aigrain E. 2011. Ciprofloxacin use in neonates: a systematic review of the literature. Pediatr. Infect. Dis. J. 30:e29-e37. http://dx.doi.org/10.1097/INF.0b013e3181fe353d.
4. Pandolfini C, Kaguelidou F, Sequi M, Jacqz-Aigrain E, Choonara I, Turner MA, Manzoni P, Bonati M. 2013. Wide intra- and inter-country variability in drug use and dosage in very-low-birth-weight newborns with severe infections. Eur. J. Clin. Pharmacol. 69:1031-1036. http://dx.doi.org/10.1007/s00228-012-1415-2.
5. Vance-Bryan K, Guay DR, Rotschafer JC. 1990. Clinical pharmacokinetics of ciprofloxacin. Clin. Pharmacokinet. 19:434-461. http://dx.doi.org/10.2165/00003088-199019060-00003.
6. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081. http://dx.doi.org/10.1128/AAC.37.5.1073.
7. van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY, Schouten MA, Girbes AR. 2008. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J. Crit. Care 23:422-430. http://dx.doi.org/10.1016/j.jcrc.2007.11.011.
8. Grondin C, Zhao W, Fakhoury M, Jacqz-Aigrain E. 2011. Determination of ciprofloxacin in plasma by micro-liquid chromatography-mass spectrometry: an adapted method for neonates. Biomed. Chromatogr. 25:827-832. http://dx.doi.org/10.1002/bmc.1523.
9. Hooker AC, Staatz CE, Karlsson MO. 2007. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm. Res. 24:2187-2197. http://dx.doi.org/10.1007/s11095-007-9361-x.
10. Lindbom L, Ribbing J, Jonsson EN. 2004. Perl-speaks-NONMEM (PsN): a Perl module for NONMEM related programming. Comput. Methods Programs. Biomed. 75:85-94. http://dx.doi.org/10.1016/j.cmpb.2003.11.003.
11. Brendel K, Comets E, Laffont C, Laveille C, Mentré F. 2006. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm. Res. 23:2036-2049. http://dx.doi.org/10.1007/s11095-006-9067-5.
12. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. 2011. Predictioncorrected visual predictive checks for diagnosing nonlinear mixed-effects modes. AAPS J. 13:143-151. http://dx.doi.org/10.1208/s12248-011-9255-z.
13. Comets E, Brendel K, Mentré F. 2008. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput. Methods Programs Biomed. 90:154-166. http://dx.doi.org/10.1016/j.cmpb.2007.12.002.
14. Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. 2011. Ciprofloxacin safety in paediatrics: a systematic review. Arch. Dis. Child. 96:874-880. http://dx.doi.org/10.1136/adc.2010.208843.
15. Sendzik J, Lode H, Stahlmann R. 2009. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int. J. Antimicrob. Agents 33:194-200. http://dx.doi.org/10.1016/j.ijantimicag.2008.08.004.
16. Drossou-Agakidou V, Roilides E, Papakyriakidou-Koliouska P, Agakidis C, Nikolaides N, Sarafidis K, Kremenopoulos G. 2004. Use of ciprofloxacin in neonatal sepsis: lack of adverse effects up to one year. Pediatr. Infect. Dis. J. 23:346-349. http://dx.doi.org/10.1097/00006454-200404000-00014.
17. Loron G, Olivier P, See H, Le Saché N, Angulo L, Biran V, Brunelle N, Besson-Lescure B, Kitzis MD, Pansiot J, Bingen E, Gressens P, Bonacorsi S, Baud O. 2011. Ciprofloxacin prevents myelination delay in neonatal rats subjected to Escherichia coli sepsis. Ann. Neurol. 69:341-351. http://dx.doi.org/10.1002/ana.22190.
18. Shane AL, Stoll BJ. 2013. Recent developments and current issues in the epidemiology, diagnosis, and management of bacterial and fungal neonatal sepsis. Am. J. Perinatol. 30:131-142. http://dx.doi.org/10.1055/s-0032-1333413.
19. Hornik CP, Fort P, Clark RH, Watt K, Benjamin DK, Jr, Smith PB, Manzoni P, Jacqz-Aigrain E, Kaguelidou F, Cohen-Wolkowiez M. 2012. Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units. Early. Hum. Dev. 88:S69-S74. http://dx.doi.org/10.1016/S0378-3782(12)70019-1.
20. Aggarwal P, Dutta S, Garg SK, Narang A. 2004. Multiple dose pharmacokinetics of ciprofloxacin in preterm babies. Indian Pediatr. 41:1001-1007.
21. Peltola H, Väärälä M, Renkonen OV, Neuvonen PJ. 1992. Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. Antimicrob. Agents Chemother. 36:1086-1090. http://dx.doi.org/10.1128/AAC.36.5.1086.
22. van den Oever HL, Versteegh FG, Thewessen EA, van den Anker JN, Mouton JW, Neijens HJ. 1998. Ciprofloxacin in preterm neonates: case report and review of the literature. Eur. J. Pediatr. 157:843-845. http://dx.doi.org/10.1007/s004310050949.
23. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. 2003. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349:1157-1167. http://dx.doi.org/10.1056/NEJMra035092.
24. Zhao W, Kaguelidou F, Biran V, Zhang D, Allegaert K, Capparelli EV, Holford N, Kimura T, Lo YL, Peris JE, Thomson A, van den Anker JN, Fakhoury M, Jacqz-Aigrain E. 2013. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. Br. J. Clin. Pharmacol. 75:1068-1080. http://dx.doi.org/10.1111/j.1365-2125.2012.04406.x.
25. Seay RE, Brundage RC, Jensen PD, Schilling CG, Edgren BE. 1994. Population pharmacokinetics of vancomycin in neonates. Clin. Pharmacol. Ther. 56:169-175. http://dx.doi.org/10.1038/clpt.1994.120.
26. Food and Drug Administration. 2014. Guidance for industry - exposure-response relationships: study design, data analysis, and regulatory applications. U.S. Food and Drug Administration, Washington, DC. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072109.pdf.
27. European Medicines Agency. 2014. Guideline on evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95 rev2). European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003417.pdf.
28. European Medicines Agency. 2014. Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. Document CPMP/EWP/2655/99. European Medicines Agency, London, United Kingdom.
29. EUCAST. 2014. Breakpoint tables for interpretation of MICs and zone diameters, version 4.0. EUCAST, Växjö, Sweden.
30. Lipman J, Gous AG, Mathivha LR, Tshukutsoane S, Scribante J, Hon H, Pinder M, Riera-Fanego JF, Verhoef L, Stass H. 2002. Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? Intensive Care Med. 28:493-500. http://dx.doi.org/10.1007/s00134-002-1212-y.
31. CLSI. 2011. Standards for antimicrobial susceptibility testing. CLSI, Wayne, PA.